Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 68

1.

Dose Selection and Validation for Ceftazidime-Avibactam in Adults with Complicated Intra-Abdominal Infections, Complicated Urinary Tract Infections and Nosocomial Pneumonia.

Das S, Li J, Riccobene T, Carrothers TJ, Newell P, Melnick D, Critchley IA, Stone GG, Nichols WW.

Antimicrob Agents Chemother. 2019 Jan 22. pii: AAC.02187-18. doi: 10.1128/AAC.02187-18. [Epub ahead of print] Review.

PMID:
30670413
2.

Ceftazidime-Avibactam Susceptibility Breakpoints against Enterobacteriaceae and Pseudomonas aeruginosa.

Nichols WW, Stone GG, Newell P, Broadhurst H, Wardman A, MacPherson M, Yates K, Riccobene T, Critchley IA, Das S.

Antimicrob Agents Chemother. 2018 Oct 24;62(11). pii: e02590-17. doi: 10.1128/AAC.02590-17. Print 2018 Nov.

PMID:
30061279
3.

Avibactam Pharmacokinetic/Pharmacodynamic Targets.

Nichols WW, Newell P, Critchley IA, Riccobene T, Das S.

Antimicrob Agents Chemother. 2018 May 25;62(6). pii: e02446-17. doi: 10.1128/AAC.02446-17. Print 2018 Jun. Review.

4.

Assessment of 30/20-Microgram Disk Content versus MIC Results for Ceftazidime-Avibactam Tested against Enterobacteriaceae and Pseudomonas aeruginosa.

Sader HS, Rhomberg PR, Huband MD, Critchley IA, Stone GG, Flamm RK, Jones RN.

J Clin Microbiol. 2018 May 25;56(6). pii: e01960-17. doi: 10.1128/JCM.01960-17. Print 2018 Jun.

5.

New Antimicrobial Agents  …  but No Susceptibility Tests!

Ambler JE, Krause KM, Steenbergen JN, Scangarella-Oman NE, Miller LA, Bhagwat SS, Serio AW, Chesnel L, Mahoney NM, Motyl MR, Critchley IA, Iaconis JP, Stone GG, Alder J, Xerri L, McCurdy SP, van Veenhuyzen DF, Grossman T, Echols RM, Williams G, Bradford PA.

Clin Infect Dis. 2016 Dec 1;63(11):1530-1531. Epub 2016 Aug 31. No abstract available.

PMID:
27581762
6.

Evolution of Ceftaroline-Resistant Mrsa in a Child with Cystic Fibrosis Following Repeated Antibiotic Exposure.

Cannavino CR, Mendes RE, Sader HS, Farrell DJ, Critchley IA, Biek D, Le J, Skochko SM, Jones RN, Bradley JS.

Pediatr Infect Dis J. 2016 Jul;35(7):813-5. doi: 10.1097/INF.0000000000001171.

PMID:
27093165
7.

Ceftazidime-avibactam for the treatment of complicated urinary tract infections and complicated intra-abdominal infections.

Mawal Y, Critchley IA, Riccobene TA, Talley AK.

Expert Rev Clin Pharmacol. 2015;8(6):691-707. doi: 10.1586/17512433.2015.1090874. Epub 2015 Sep 30. Review.

PMID:
26420166
8.

Accuracy of the Thermo Fisher Scientific (Sensititre™) dry-form broth microdilution MIC product when testing ceftaroline.

Jones RN, Holliday NM, Critchley IA.

Diagn Microbiol Infect Dis. 2015 Apr;81(4):280-2. doi: 10.1016/j.diagmicrobio.2014.12.010. Epub 2014 Dec 30.

PMID:
25623933
9.

Serotype distribution and antimicrobial susceptibility of USA Streptococcus pneumoniae isolates collected prior to and post introduction of 13-valent pneumococcal conjugate vaccine.

Mendes RE, Costello AJ, Jacobs MR, Biek D, Critchley IA, Jones RN.

Diagn Microbiol Infect Dis. 2014 Sep;80(1):19-25. doi: 10.1016/j.diagmicrobio.2014.05.020. Epub 2014 May 24.

PMID:
24974272
10.

Decreased ceftriaxone susceptibility in emerging (35B and 6C) and persisting (19A) Streptococcus pneumoniae serotypes in the United States, 2011-2012: ceftaroline remains active in vitro among β-lactam agents.

Mendes RE, Biek D, Critchley IA, Farrell DJ, Sader HS, Jones RN.

Antimicrob Agents Chemother. 2014 Aug;58(8):4923-7. doi: 10.1128/AAC.02976-14. Epub 2014 May 27.

11.

Pharmacokinetic-pharmacodynamic target attainment analyses to evaluate in vitro susceptibility test interpretive criteria for ceftaroline against Staphylococcus aureus and Streptococcus pneumoniae.

Van Wart SA, Ambrose PG, Rubino CM, Khariton T, Riccobene TA, Friedland HD, Critchley IA, Bhavnani SM.

Antimicrob Agents Chemother. 2014;58(2):885-91. doi: 10.1128/AAC.01680-13. Epub 2013 Nov 25.

12.

Activity of ceftaroline and epidemiologic trends in Staphylococcus aureus isolates collected from 43 medical centers in the United States in 2009.

Richter SS, Heilmann KP, Dohrn CL, Riahi F, Costello AJ, Kroeger JS, Biek D, Critchley IA, Diekema DJ, Doern GV.

Antimicrob Agents Chemother. 2011 Sep;55(9):4154-60. doi: 10.1128/AAC.00315-11. Epub 2011 Jun 27.

13.

FOCUS 2: a randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia.

Low DE, File TM Jr, Eckburg PB, Talbot GH, David Friedland H, Lee J, Llorens L, Critchley IA, Thye DA; FOCUS 2 investigators.

J Antimicrob Chemother. 2011 Apr;66 Suppl 3:iii33-44. doi: 10.1093/jac/dkr097.

PMID:
21482568
14.

FOCUS 1: a randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia.

File TM Jr, Low DE, Eckburg PB, Talbot GH, Friedland HD, Lee J, Llorens L, Critchley IA, Thye DA; FOCUS 1 investigators.

J Antimicrob Chemother. 2011 Apr;66 Suppl 3:iii19-32. doi: 10.1093/jac/dkr096.

PMID:
21482566
15.

Review of ceftaroline fosamil microbiology: integrated FOCUS studies.

Critchley IA, Eckburg PB, Jandourek A, Biek D, Friedland HD, Thye DA.

J Antimicrob Chemother. 2011 Apr;66 Suppl 3:iii45-51. doi: 10.1093/jac/dkr098. Review.

PMID:
21482569
16.

Ceftaroline fosamil: a novel broad-spectrum cephalosporin with expanded anti-Gram-positive activity.

Biek D, Critchley IA, Riccobene TA, Thye DA.

J Antimicrob Chemother. 2010 Nov;65 Suppl 4:iv9-16. doi: 10.1093/jac/dkq251. Review.

PMID:
21115457
17.

Activity of ceftaroline against recent emerging serotypes of Streptococcus pneumoniae in the United States.

Jacobs MR, Good CE, Windau AR, Bajaksouzian S, Biek D, Critchley IA, Sader HS, Jones RN.

Antimicrob Agents Chemother. 2010 Jun;54(6):2716-9. doi: 10.1128/AAC.01797-09. Epub 2010 Mar 22.

18.

Spectrum of activity and mode of action of REP3123, a new antibiotic to treat Clostridium difficile infections.

Critchley IA, Green LS, Young CL, Bullard JM, Evans RJ, Price M, Jarvis TC, Guiles JW, Janjic N, Ochsner UA.

J Antimicrob Chemother. 2009 May;63(5):954-63. doi: 10.1093/jac/dkp041. Epub 2009 Mar 3.

PMID:
19258353
19.

Inhibitory effect of REP3123 on toxin and spore formation in Clostridium difficile, and in vivo efficacy in a hamster gastrointestinal infection model.

Ochsner UA, Bell SJ, O'Leary AL, Hoang T, Stone KC, Young CL, Critchley IA, Janjic N.

J Antimicrob Chemother. 2009 May;63(5):964-71. doi: 10.1093/jac/dkp042. Epub 2009 Feb 26.

PMID:
19251726
20.

Quinazolin-2-ylamino-quinazolin-4-ols as novel non-nucleoside inhibitors of bacterial DNA polymerase III.

Guiles J, Sun X, Critchley IA, Ochsner U, Tregay M, Stone K, Bertino J, Green L, Sabin R, Dean F, Dallmann HG, McHenry CS, Janjic N.

Bioorg Med Chem Lett. 2009 Feb 1;19(3):800-2. doi: 10.1016/j.bmcl.2008.12.038. Epub 2008 Dec 13.

PMID:
19109016
21.

Recent advances in the preclinical evaluation of the topical antibacterial agent REP8839.

Critchley IA, Ochsner UA.

Curr Opin Chem Biol. 2008 Aug;12(4):409-17. doi: 10.1016/j.cbpa.2008.06.011. Epub 2008 Jul 11. Review.

PMID:
18620074
22.

Prevalence of serotype 19A Streptococcus pneumoniae among isolates from U.S. children in 2005-2006 and activity of faropenem.

Critchley IA, Jacobs MR, Brown SD, Traczewski MM, Tillotson GS, Janjic N.

Antimicrob Agents Chemother. 2008 Jul;52(7):2639-43. doi: 10.1128/AAC.00310-08. Epub 2008 Apr 28.

23.

Susceptibility of Staphylococcus aureus isolated from skin and wound infections in the United States 2005-07: laboratory-based surveillance study.

Tillotson GS, Draghi DC, Sahm DF, Tomfohrde KM, Del Fabro T, Critchley IA.

J Antimicrob Chemother. 2008 Jul;62(1):109-15. doi: 10.1093/jac/dkn149. Epub 2008 Apr 8.

PMID:
18397923
24.

National and regional assessment of antimicrobial resistance among community-acquired respiratory tract pathogens identified in a 2005-2006 U.S. Faropenem surveillance study.

Critchley IA, Brown SD, Traczewski MM, Tillotson GS, Janjic N.

Antimicrob Agents Chemother. 2007 Dec;51(12):4382-9. Epub 2007 Oct 1.

25.

Activity of faropenem against middle ear fluid pathogens from children with acute otitis media in Costa Rica and Israel.

Stone KC, Dagan R, Arguedas A, Leibovitz E, Wang E, Echols RM, Janjic N, Critchley IA.

Antimicrob Agents Chemother. 2007 Jun;51(6):2230-5. Epub 2007 Mar 26.

26.

Activity of faropenem tested against Neisseria gonorrhoeae isolates including fluoroquinolone-resistant strains.

Jones RN, Critchley IA, Whittington WL, Janjic N, Pottumarthy S.

Diagn Microbiol Infect Dis. 2005 Dec;53(4):311-7. Epub 2005 Nov 2.

PMID:
16269221
27.

Mode of action and biochemical characterization of REP8839, a novel inhibitor of methionyl-tRNA synthetase.

Ochsner UA, Young CL, Stone KC, Dean FB, Janjic N, Critchley IA.

Antimicrob Agents Chemother. 2005 Oct;49(10):4253-62.

28.

Antibacterial activity of REP8839, a new antibiotic for topical use.

Critchley IA, Young CL, Stone KC, Ochsner UA, Guiles J, Tarasow T, Janjic N.

Antimicrob Agents Chemother. 2005 Oct;49(10):4247-52.

29.

Development of a standardized susceptibility test for campylobacter with quality-control ranges for ciprofloxacin, doxycycline, erythromycin, gentamicin, and meropenem.

McDermott PF, Bodeis SM, Aarestrup FM, Brown S, Traczewski M, Fedorka-Cray P, Wallace M, Critchley IA, Thornsberry C, Graff S, Flamm R, Beyer J, Shortridge D, Piddock LJ, Ricci V, Johnson MM, Jones RN, Reller B, Mirrett S, Aldrobi J, Rennie R, Brosnikoff C, Turnbull L, Stein G, Schooley S, Hanson RA, Walker RD.

Microb Drug Resist. 2004 Summer;10(2):124-31.

PMID:
15256027
30.

Optimal use of antibiotic resistance surveillance systems.

Critchley IA, Karlowsky JA.

Clin Microbiol Infect. 2004 Jun;10(6):502-11. Review.

31.

Antibiotic susceptibility of isolates of Bacillus anthracis, a bacterial pathogen with the potential to be used in biowarfare.

Jones ME, Goguen J, Critchley IA, Draghi DC, Karlowsky JA, Sahm DF, Porschen R, Patra G, DelVecchio VG.

Clin Microbiol Infect. 2003 Sep;9(9):984-6.

32.

In vitro susceptibility of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis: a European multicenter study during 2000-2001.

Jones ME, Blosser-Middleton RS, Critchley IA, Karlowsky JA, Thornsberry C, Sahm DF.

Clin Microbiol Infect. 2003 Jul;9(7):590-9.

33.

Antimicrobial susceptibility of 840 clinical isolates of Haemophilus influenzae collected in four European countries in 2000-2001.

Blosser-Middleton R, Sahm DF, Thornsberry C, Jones ME, Hogan PA, Critchley IA, Karlowsky JA.

Clin Microbiol Infect. 2003 May;9(5):431-6.

34.
35.

In vitro synergy studies using aztreonam and fluoroquinolone combinations against six species of Gram-negative bacilli.

Critchley IA, Sahm DF, Kelly LJ, Karlowsky JA.

Chemotherapy. 2003 May;49(1-2):44-8.

PMID:
12714810
36.

Baseline study to determine in vitro activities of daptomycin against gram-positive pathogens isolated in the United States in 2000-2001.

Critchley IA, Blosser-Middleton RS, Jones ME, Thornsberry C, Sahm DF, Karlowsky JA.

Antimicrob Agents Chemother. 2003 May;47(5):1689-93.

37.

Factors associated with relative rates of antimicrobial resistance among Streptococcus pneumoniae in the United States: results from the TRUST Surveillance Program (1998-2002).

Karlowsky JA, Thornsberry C, Jones ME, Evangelista AT, Critchley IA, Sahm DF; TRUST Surveillance Program.

Clin Infect Dis. 2003 Apr 15;36(8):963-70. Epub 2003 Apr 2.

PMID:
12684907
38.

Activity of daptomycin against susceptible and multidrug-resistant Gram-positive pathogens collected in the SECURE study (Europe) during 2000-2001.

Critchley IA, Draghi DC, Sahm DF, Thornsberry C, Jones ME, Karlowsky JA.

J Antimicrob Chemother. 2003 Mar;51(3):639-49.

PMID:
12615866
39.

Activity of faropenem, a new furanem, against European respiratory pathogens collected during 2000-2001: a comparison with other beta-lactam agents.

Jones ME, Blosser-Middleton RS, Critchley IA, Karlowsky JA, Thornsberry C, Sahm DF.

J Antimicrob Chemother. 2003 Jan;51(1):196-9. No abstract available.

PMID:
12493818
40.

The activity of levofloxacin and comparator agents against clinical isolates of Streptococcus pneumoniae collected worldwide during 1999 and 2000.

Jones ME, Blosser-Middleton RS, Critchley IA, Thornsberry C, Sahm DF, Yamakita J, Akasaki M, Karlowsky JA.

Chemotherapy. 2002 Dec;48(5):232-7.

PMID:
12476039
41.

Phenotypic and genotypic analysis of levofloxacin-resistant clinical isolates of Streptococcus pneumoniae collected in 13 countries during 1999-2000.

Critchley IA, Blosser-Middleton RS, Jones ME, Karlowsky JA, Karginova EA, Thornsberry C, Sahm DF.

Int J Antimicrob Agents. 2002 Aug;20(2):100-7.

PMID:
12297358
42.

Antimicrobial susceptibilities of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis isolated in two successive respiratory seasons in the US.

Karlowsky JA, Draghi DC, Thornsberry C, Jones ME, Critchley IA, Sahm DF.

Int J Antimicrob Agents. 2002 Aug;20(2):76-85.

PMID:
12297355
43.

Longitudinal assessment of antipneumococcal susceptibility in the United States.

Jones ME, Karlowsky JA, Blosser-Middleton R, Critchley IA, Karginova E, Thornsberry C, Sahm DF.

Antimicrob Agents Chemother. 2002 Aug;46(8):2651-5.

44.

In vitro activity of levofloxacin against contemporary clinical isolates of Legionella pneumophila, Mycoplasma pneumoniae and Chlamydia pneumoniae from North America and Europe.

Critchley IA, Jones ME, Heinze PD, Hubbard D, Engler HD, Evangelista AT, Thornsberry C, Karlowsky JA, Sahm DF.

Clin Microbiol Infect. 2002 Apr;8(4):214-21.

45.

Determining Linezolid's baseline in vitro activity in Canada using gram-positive clinical isolates collected prior to its national release.

Karlowsky JA, Kelly LJ, Critchley IA, Jones ME, Thornsberry C, Sahm DF.

Antimicrob Agents Chemother. 2002 Jun;46(6):1989-92.

46.
47.

Antimicrobial resistance among respiratory pathogens collected in Thailand during 1999-2000.

Critchley IA, Blosser-Middleton R, Jones ME, Yamakita J, Aswapokee N, Chayakul P, Tharavichitukul P, Vibhagool A, Thornsberry C, Karlowsky JA, Sahm DF.

J Chemother. 2002 Apr;14(2):147-54.

PMID:
12017369
48.

Antimicrobial resistance in respiratory pathogens isolated in Brazil during 1999-2000.

Critchley IA, Blosser RS, Karlowsky JA, Yamakita J, Barth A, Sader HS, Mendes C, Teixeira L, Rossi F, Dias CA, Jones ME, Thornsberry C, Sahm DF.

Braz J Infect Dis. 2001 Dec;5(6):294-304. Epub 2003 Feb 21.

49.

Proficiency of Italian clinical laboratories in detecting reduced glycopeptide susceptibility in Enterococcus and Staphylococcus spp. using routine laboratory methodologies.

Jones ME, Gesu G, Ortisi G, Sahm DF, Critchley IA, Goglio A; Associazione Microbiologi Clinici Italiani (AMCLI) Committee for Antibiotics.

Clin Microbiol Infect. 2002 Feb;8(2):101-11.

50.

Molecular characterization of vancomycin-resistant Enterococci repopulating the gastrointestinal tract following treatment with a novel glycolipodepsipeptide, ramoplanin.

Baden LR, Critchley IA, Sahm DF, So W, Gedde M, Porter S, Moellering RC Jr, Eliopoulos G.

J Clin Microbiol. 2002 Apr;40(4):1160-3.

Supplemental Content

Loading ...
Support Center